Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.79 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269218 | 1.00 | ALDH1A1 (0.79) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL820663 | 1.00 | ALDH1A1 (0.79) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL4878921 | 0.88 | ALDH1A1 (1.00) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL725197 | 0.82 | ALDH1A1 (0.70) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL9228116 | 0.82 | ALDH1A1 (0.70) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL12856664 | 0.82 | ALDH1A1 (0.70) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL580157 | 0.82 | ALDH1A1 (0.73) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL579722 | 0.82 | ALDH1A1 (0.65) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL9223130 | 0.81 | ALDH1A1 (0.68) | ALDH1A1ALDH2HPGDGAAHSD17B10 | |
| SCHEMBL14852665 | 0.81 | ALDH1A1 (0.68) | ALDH1A1ALDH2HPGDGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1584621-B1 | A process for the preparation of tolterodine and intermediates thereof | DIPHARMA FRANCIS SRL (IT) | 2007-06-13 | — | — | EP | claimed |
| US-7119212-B2 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2006-10-10 | — | — | US | claimed |
| EP-1584621-A1 | A process for the preparation of tolterodine and intermediates thereof | Dipharma S.p.A. (IT) | 2005-10-12 | — | — | EP | claimed |
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | US | claimed |
| US-9309215-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20140228434-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | UCB PHARMA GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-8742140-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20110281952-A1 | DEUTERIUM-ENRICHED TOLTERODINE | PROTIA, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110245338-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | UCB PHARMA GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| US-7982058-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090192224-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | SCHWARZ PHARMA AG (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090062398-A1 | DEUTERIUM-ENRICHED TOLTERODINE | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20070010691-A1 | Enantioselective synthesis of enantiomerically enriched compounds | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2007-01-11 | — | — | US | disclosed |
| US-7119212-B2 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2006-10-10 | — | — | US | disclosed |
| US-7119212-B2 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2006-10-10 | — | — | US | disclosed |
| JP-2005281311-A | METHOD FOR PRODUCING TOLTERODINE AND ITS INTERMEDIATE | DIPHARMA SPA | 2005-10-13 | — | — | JP | disclosed |
| EP-1584621-A1 | A process for the preparation of tolterodine and intermediates thereof | Dipharma S.p.A. (IT) | 2005-10-12 | — | — | EP | disclosed |
| EP-1584621-A1 | A process for the preparation of tolterodine and intermediates thereof | Dipharma S.p.A. (IT) | 2005-10-12 | — | — | EP | disclosed |
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | US | disclosed |
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | CYP2B6, UGT1A6, CYP2D6 | ALDH1A1 1277/4885ALDH2 1890/4885HPGD 1820/4885 |
| US-20090062398-A1 | DEUTERIUM-ENRICHED TOLTERODINE | SLC6A3, AVPR2, TBCD | ALDH1A1 3032/4885ALDH2 3195/4885HPGD 517/4885 |
| US-20090192224-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | CYP1B1, NISCH, HSD17B7 | ALDH1A1 780/4885ALDH2 1270/4885HPGD 498/4885 |
| US-20110245338-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | CYP1B1, NISCH, HSD17B7 | ALDH1A1 780/4885ALDH2 1270/4885HPGD 498/4885 |
| US-20070010691-A1 | Enantioselective synthesis of enantiomerically enriched compounds | CYP8B1, SRD5A2, CYP11B2 | ALDH1A1 876/4885ALDH2 1169/4885HPGD 692/4885 |
| US-20110281952-A1 | DEUTERIUM-ENRICHED TOLTERODINE | SLC6A3, AVPR2, TBCD | ALDH1A1 3032/4885ALDH2 3195/4885HPGD 517/4885 |
| US-20140228434-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | CYP1B1, NISCH, HSD17B7 | ALDH1A1 780/4885ALDH2 1270/4885HPGD 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.